Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 9, 2010

Capgemini to Offer Cegedim Dendrite’s Software Solutions

  • Cegedim Dendrite and Capgemini agreed to jointly offer software solutions as well as consulting and technology services to life science firms. Specifically, Capgemini will provide consulting and implementation services associated with Cegedim Dendrite’s AggregateSpend360™ and Nucleus 360™ tools.

    AggregateSpend360 enables compliance with changing regulations. Nucleus 360 establishes a master definition of the customer in a centralized repository and implements data governance and quality processes.

    Through the alliance, biotech, pharma, and medical device firms will be able to take advantage of the combination of Cegedim Dendrite software and Capgemini’s expertise in industry best practices. The companies will work together to help clients confront the challenges of complying with an increasing number of complex federal and state requirements for disclosure reporting on marketing, clinical, advertising, and sales promotion expenses, commonly known as aggregate spend reporting.

    Additionally, maintaining an accurate customer database when customer data is housed in multiple databases from disparate systems will also be enabled.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »